Duoleukin-221

N/A

Report date: 2023/03/12 14:23:25

Base Information

Drug NameDuoleukin-221
Drug Alias NameDuoleukin-221
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionInterleukin-2 replacements
TargetsInterleukin-2
Therapy Area/IndicationsAutoimmune Diseases of the Nervous SystemNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnwita Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnwita Biosciences Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases of the Nervous SystemNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A